Matthew Paul Kowalsky

CIK: 0001705824

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ENTA

ENANTA PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
1.3K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
4.2K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Tax Payment(F)
Direct
1.9K shares at avg. $14.25$27K
ENTA
ENANTA PHARMACEUTICALS INC
Nov 25, 2025
Award(A)
Stock Option (right to buy)
Direct
90K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Nov 27, 2024
Award(A)
Stock Option (right to buy)
Direct
75K shares-

		Type	Shares	Price		Ownership
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	1,318	-	$0	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	4,175	-	$0	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	1,902	$14.25	$27,104	Direct
Nov 25, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Nov 27, 2024	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	75,000	-	-	Direct

1-5 of 5 transactions

About Kowalsky Matthew Paul

Kowalsky Matthew Paul (SEC CIK 0001705824) files insider reports with the SEC as Chief Legal Officer of ENANTA PHARMACEUTICALS INC (ENTA).

Signal8 holds 3 ownership filings by Kowalsky Matthew Paul, all Form 4s, filed between Nov 27, 2024 and Feb 13, 2026. Those filings report 5 transactions, from Nov 27, 2024 to Feb 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kowalsky Matthew Paul's filings is in WATERTOWN, MA.

Recent filings by Kowalsky Matthew Paul

Feb 12, 2026: Grants or awards of ENTA shares (2 lines, Form 4, code A).
Feb 12, 2026: Tax withholding of ENTA shares (Form 4, code F).
Nov 25, 2025: Grant or award of ENTA derivative securities (Form 4, code A).
Nov 27, 2024: Grant or award of ENTA derivative securities (Form 4, code A).

Other insiders filing for ENANTA PHARMACEUTICALS INC (ENTA)

Rottinghaus Scott T., Chief Medical Officer
Vance Terry, Director
Russell Lesley, Director
Peterson Kristine, Director
Hata Yujiro S, Director
FOLETTA MARK G, Director

How to read Form 4 transaction codes